keytruda merck - Search News

News

Merck, Delaware and Keytruda

Merck plans to move manufacturing of its biggest drug, Keytruda, to a new US factory and lab in Delaware

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future drugs to market. Keytruda is currently made in Ireland and by contract manufacturers in the United States.

Seeking Alpha on MSN · 1d

Merck to build $1B Delaware plant to ensure domestic supply of Keytruda

Merck (NYSE:MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical company to boost domestic investment as industry-targeted tariffs loom. This 470,

The American Bazaar · 1h

Pharmaceutical company Merck to invest $1 billion in Delaware plant

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with President Donald Trump's tariffs

Fierce Pharma2d

AACR: Merck's Keytruda prevents head and neck cancer from returning in industry-first win

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Does Merck Stock Have Room For Growth?

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

STAT1d

Pharmalittle: We’re reading about FDA chaos delaying a rare disease drug, Merck’s U.S. investment, and more

Merck will grow its U.S. manufacturing footprint with a $1 billion plant, making it the latest drugmaker to invest in the U.S ...

Devdiscourse10h

Breakthrough in Cancer Treatments: Zongertinib, Jemperli, and Keytruda Making Waves

Exciting developments in cancer treatment were unveiled at the AACR meeting. Boehringer Ingelheim's zongertinib shows a 71% ...

Merck (NYSE:MRK) Presents Promising KEYTRUDA Trial Data at AACR 2025 Meeting

Merck (NYSE:MRK) recently announced promising results from its Phase 3 KEYNOTE-689 trial of KEYTRUDA, presented at the AACR Annual Meeting, which seems likely to have bolstered investor confidence, ...

Fierce Pharma6d

Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

6don MSN

Merck Earnings Beat Expectations. Investors Are Still Worried.

Merck delivered better-than-expected first-quarter financial results Thursday, but it wasn’t enough to lift the gloom that ...

6don MSN

Merck Cuts 2025 Outlook on Tariffs, Charges

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results